A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of
talazoparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is to compare the efficacy and
safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed
ovarian, fallopian tube, and peritoneal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Medivation, Inc. Pfizer
Collaborators:
Medivation, Inc. Myriad Genetic Laboratories, Inc.